Aprea Therapeutics, Inc. (APRE): Nasdaq/NYSE listing notice — Aprea Therapeutics regains compliance with Nasdaq minimum $10M stockholders' equity requirement

Aprea Therapeutics, Inc.

Received deficiency letter on Aug 15, 2022 for failing minimum $10M stockholders' equity rule.
Based on Q3 2022 10-Q showing equity of ~$26.6M, Nasdaq confirmed compliance regained.
Listing on Nasdaq Global Select Market continues without risk of delisting.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aprea Therapeutics, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5450(b)(1)(A)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: stockholders equity
Rules: 5450(b)(1)(A)

Exact text from the filing

set forth in Listing Rule 5450(b)(1)(A) (the “Rule”). Based on the Company’s Form 10-Q for the period ended September 30, 2022, evidencing stockholders’ equity of approximately $26.6 million, the Staff has determined that the Company has regained compliance with the Rule. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-119551

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.